Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice

J Neurosci. 2009 Feb 11;29(6):1773-83. doi: 10.1523/JNEUROSCI.5685-08.2009.

Abstract

PTEN (phosphatase and tensin homolog deleted on chromosome ten) is a lipid phosphatase that counteracts the function of phosphatidylinositol-3 kinase (PI3K). Loss of function of PTEN results in constitutive activation of AKT and downstream effectors and correlates with many human cancers, as well as various brain disorders, including macrocephaly, seizures, Lhermitte-Duclos disease, and autism. We previously generated a conditional Pten knock-out mouse line with Pten loss in limited postmitotic neurons in the cortex and hippocampus. Pten-null neurons developed neuronal hypertrophy and loss of neuronal polarity. The mutant mice exhibited macrocephaly and behavioral abnormalities reminiscent of certain features of human autism. Here, we report that rapamycin, a specific inhibitor of mammalian target of rapamycin complex 1 (mTORC1), can prevent and reverse neuronal hypertrophy, resulting in the amelioration of a subset of PTEN-associated abnormal behaviors, providing evidence that the mTORC1 pathway downstream of PTEN is critical for this complex phenotype.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Autistic Disorder / metabolism*
  • Autistic Disorder / pathology
  • Female
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Neurons / drug effects
  • Neurons / metabolism*
  • Neurons / pathology
  • PTEN Phosphohydrolase / deficiency*
  • PTEN Phosphohydrolase / metabolism
  • Sirolimus / pharmacology
  • Transcription Factors / antagonists & inhibitors*
  • Transcription Factors / metabolism*

Substances

  • Crtc1 protein, mouse
  • Transcription Factors
  • PTEN Phosphohydrolase
  • PTEN protein, human
  • Sirolimus